R. Rajasingham, R. M. Smith, and B. J. Park, Global burden of disease of HIVassociated cryptococcal meningitis: an updated analysis, Lancet Infect Dis, vol.17, pp.873-81, 2017.

K. M. Gaskell, C. Rothe, and R. Gnanadurai, A prospective study of mortality from cryptococcal meningitis following treatment induction with 1200 mg oral fluconazole in, PLOS One, vol.9, p.110285, 2014.

N. Longley, C. Muzoora, and K. Taseera, Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda, Clin Infect Dis, vol.47, pp.1556-61, 2008.

C. Rothe, D. J. Sloan, and P. Goodson, A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in, PLOS One, vol.8, p.67311, 2013.

J. C. Nussbaum, A. Jackson, and D. Namarika, Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi, Clin Infect Dis, vol.50, pp.338-382, 2010.

S. F. Molloy, C. Kanyama, and R. S. Heyderman,

, Advancing Cryptococcal Meningitis Treatment for Africa Trial Study Team. Antifungal combinations for treatment of cryptococcal meningitis in Africa, N Engl J Med, vol.378, pp.1004-1021, 2018.

T. Chen, L. Mwenge, and S. Lakhi, Advancing Cryptococcal Meningitis Treatment for Africa Trial Team. Health care costs and deaths prevented by ACTA trial treatments for cryptococcal meningitis: a comparison between 5 induction strategies in sub Saharan Africa, Clin Infect Dis, 2019.

, Guidelines for the diagnosis, prevention, and management of cryptococcal disease in HIV-infected adults, adolescents and children, Geneva: World Health Organization. Licence: CC BY, 2018.

M. Drummond and M. Sculpher, Common methodological flaws in economic evaluations, Med Care, vol.43, pp.5-14, 2005.

R. Rajasingham, M. A. Rolfes, K. E. Birkenkamp, D. B. Meya, and D. R. Boulware, Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis, PLOS Med, vol.9, p.1001316, 2012.

L. F. Johnson, J. Mossong, and R. E. Dorrington, Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies, PLOS Med, vol.10, p.1001418, 2013.

S. Nsanzimana, E. Remera, and S. Kanters, Life expectancy among HIV-positive patients in Rwanda: a retrospective observational cohort study, Lancet Glob Health, vol.3, pp.169-77, 2015.

A. Loyse, J. Burry, and J. Cohn, Leave no-one behind: Responding to new evidence and guidelines for the management of cryptococcal meningitis in low-and middle-income countries, Epub ahead of print, pp.30493-30499, 2018.

J. G. Bartlett, P. G. Auwaerter, and P. A. Pham, Johns Hopkins ABX guide: diagnosis and treatment of infectious diseases, 2012.

A. Harsanyi, A. Conte, L. Pichon, A. Rabion, S. Grenier et al., One-step continuous flow synthesis of antifungal WHO essential medicine flucytosine using fluorine, Org Process Res Dev, vol.21, pp.273-279, 2017.

S. Horton, Cost-effectiveness analysis in disease control priorities, Disease control priorities, vol.9, pp.147-56, 2018.

J. N. Jarvis, T. Bicanic, and A. Loyse, Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: implications for improving outcomes, Clin Infect Dis, vol.58, pp.736-781, 2014.